Aktieanalys

Hansa Biopharma: Soft Idefirix sales in Europe and a slipping US timetable for the US launch - Redeye

Redeye Publicerad: 12 Oct 2023 14:13

Hansa has provided a clinical update and top-line results ahead of the Q3 results. After a relatively strong Q2, deliveries have been slow during Q3 with product sales of SEK 16m, which aligns with the modest Q1 earlier in 2023. Enrollments to the US ConfIdes study have increased to 89 (76), and the number of sites has increased to 25 (20) due to a slow randomization process. Earlier, Hansa expected the randomization process to be complete in late 2023. Hansa is targeting a submission by 2025 (2024).

Länk till analysen i sin helhet: https://www.redeye.se/research/946727/hansa-biopharma-soft-idefirix-sales-in-europe-and-a-slipping-us-timetable-for-the-us-launch?utm_source=finwire&utm_medium=RSS

Nyheter om Hansa Biopharma

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!